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PROGNOSIS PESAKIT-PESAKIT PENYAKIT GINJAL KRONIK (CKD) 
YANG TAK-BERGANTUNGAN DIALISIS (NDD) DAN HASIL TERAPI 
DIURETIK MELALUI SPEKTROSKOPI BIOIMPEDANS 
ABSTRAK 
Penyakit ginjal kronik (CKD) merupakan masalah kesihatan global yang 
mempengaruhi 10% daripada populasi dunia. Walaupun terdapat peningkatan insiden 
penyakit renal tahap akhir (ESRD) di Malaysia, tiada catatan mengenai kelaziman 
dan juga hasil pemeriksaan daripada peringkat pra-dialisis CKD.  Tambahan pula, 
sorotan kajian awal menunjukkan peranan diuretik masih kontroversi dan beban 
bendalir berlebihan dalam progresi CKD.  Oleh itu, satu kajian dua fasa telah 
dijalankan untuk menilai prognosis pesakit-pesakit CKD yang tidak bergantung pada 
dialisis (NDD) secara retrospektif manakala tahap kemerosotan buah pinggang 
dengan terapi diuretik dan hubungan antara diuretik dan beban bendalir berlebihan 
diperhatikan secara prospektif. Dalam fasa retrospektif, sejumlah 621 pesakit dengan 
anggaran kadar penapisan glomerular (eGFR) pada 15-59 ml / min / 1.73m2 (tahap 
CKD 3 & 4) telah dipilih dan di ikuti untuk tempoh 10 tahun atau sehingga ESRD 
atau kematian, yang mana terlebih dahulu berlaku.  Perkembangan keseluruhan 
penyakit diperhatikan dalam 372 (60%) pesakit, manakala 113 (18%) pesakit telah 
meninggal dunia. Dalam kalangan pesakit dengan tahap 3 CKD, 21% telah 
berkembang ke tahap 4, 10% telah berkembang ke tahap 5ND (tidak dialisis) dan 
31% untuk terapi penggantian buah pinggang (RRT) manakala kematian 
diperhatikan pada 16% pesakit.  Sementara itu, 8% pesakit dengan tahap 4 CKD  
berkembang ke tahap 5ND, 31% kepada RRT dan kematian diperhatikan dalam 24% 
kes. Pesakit dengan penyakit kardiovaskular (CVD), tekanan darah sistolik lebih 
xviii 
 
tinggi, tahap fosfat tinggi, proteinuria berat, hematuria mikroskopik dan penggunaan 
diuretik lebih cenderung mengalami ESRD. Pada awalnya ( apabila pesakit-pesakit 
dipilih), peningkatan usia, eGFR rendah, tekanan darah sistolik rendah, hemoglobin 
rendah dan kencing manis merupakan peramal-peramal penting bagi mortaliti 
manakala wanita telah didapati dapat megurangkan risiko mortaliti. Dalam fasa 
prospektif, sejumlah 312 pesakit NDD-CKD telah disusuli selama satu tahun. Beban 
bendalir berlebihan telah dinilai melalui spektroskopi bioimpedans (BIS). Sejumlah 
144 subjek diprekripsikan dengan diuretik. Penggunaan diuretik telah dikaitkan 
secara ketara dengan penurunan eGFR dalam setiap kategori status bendalir dengan 
penurunan maksimum diperhatikan pada pesakit hipervolemik (-5.1 ± 2.1 ml / min / 
1.73m2) yang menggunakan diuretik gabungan. Sejumlah 36 (11.5%) pesakit telah 
memulakan RRT manakala 2 (0.64%) kes kematian telah diperhatikan pada akhir 
susulan. Selain itu, telah diperhatikan bahawa utilisasi diuretik adalah rendah 
kalangan pesakit hipervolemik manakala lebih preskripsi diuretik diperhatikan pada 
pesakit-pesakit bukan hipertensi yang euvolemik dan hipovolemik. Kesimpulannya, 
penemuan terkini menunjukkan bahawa pesakit lebih cenderung kepada ESRD 
daripada kematian. Kepentingan utama harus diberikan kepada peringkat CKD yang 
sederhana bagi melambatkan malah mungkin dapat membalikkan perkembangan 
CKD. Berkenaan dengan penggunaan diuretik, dicadangkan bahawa ia adalah 
sebagai prediktor bagi hasil advers terhadap ginjal. Spektroskopi Bioimpedans (BIS) 
berupaya membantu para penjagaan kesihatan profesiona-profesional penjagaan 
kesihatan untuk mengenal pasti pesakit-pesakit CKD dengan bebanan bendalir 
berlebihan dan memberikan farmakoterapi individu mengikut keperluan-keperluan 
klinikal pesakit.  
xix 
 
PROGNOSIS OF NON-DIALYSIS DEPENDENT (NDD) CHRONIC KIDNEY 
DISEASE (CKD) PATIENTS AND OUTCOMES OF DIURETIC THERAPY 
BY USING BIOIMPEDANCE SPECTROSCOPY 
ABSTRACT 
Chronic kidney disease (CKD) is a global health concern effecting 10% of 
world population. Despite escalating incidence of ESRD in Malaysia, there is no 
record about prevalence as well as outcomes of pre-dialysis stages of CKD. 
Moreover, preliminary literature search showed controversial role of diuretics and 
fluid overload in CKD progression. Therefore, a two phase study was conducted to 
evaluate prognosis of non-dialysis dependent (NDD) CKD patients retrospectively 
while the extent of renal deterioration with diuretic therapy and relationship between 
diuretics and fluid overload was observed during prospective phase of the study. In 
the retrospective phase, a total of 621 patients with estimated glomerular filtration 
rate (eGFR) of 15-59ml/min/1.73m
2 
(CKD stage 3 & 4) were selected and followed 
up for 10 years or until ESRD or death, whichever occurred first. Overall disease 
progression was observed in 372 (60%) patients while 113 (18%) patient died. With 
respect to CKD staging, both mortality and progression to stage 5ND was more 
prevalent in CKD stage 4 patients. Among patients with CKD stage 3, 21% 
progressed to stage 4, 10% to stage 5ND (non-dialysis) and 31% to renal 
replacement therapy (RRT) while mortality was observed in 16% patients. On the 
other hand, 8% patients with CKD stage 4 progressed to stage 5ND, 31% to RRT and 
mortality was observed in 24% cases. Patients with cardiovascular disease (CVD), 
higher systolic blood pressure, elevated phosphate levels, heavy proteinuria, 
microscopic hematuria and use of diuretics were more likely to develop ESRD. At 
xx 
 
baseline (when patients were enrolled), advance age, low eGFR, low systolic blood 
pressure, low hemoglobin and diabetes were found to be significant predictors of 
mortality while female gender reduced risk of mortality. In the prospective phase, a 
total 312 NDD-CKD patients were followed-up for one year. Fluid overload was 
assessed via Bioimpedance spectroscopy (BIS). A total of 144 subjects were 
prescribed with diuretics. Diuretics use was significantly associated with decline in 
eGFR within each category of fluid status with maximum decline observed in 
hypervolemic patients (-5.1±2.1 ml/min/1.73m
2
) using combination diuretics. A total 
of 36 (11.5%) patients initiated RRT while 2 (0.64%) mortal cases were observed at 
the end of follow-up. Moreover, underutilization of diuretics was observed in 
hypervolemic patients while more diuretic prescriptions were noted in euvolemic and 
hypovolemic non-hypertensive patients. In conclusion, current findings suggest that 
patients are more likely to develop ESRD than death. Prime importance should be 
given to mild forms of CKD to retard and even reverse CKD progression. With 
respect to diuretic use, it is cautiously suggested that diuretic use is an independent 
predictor of adverse renal outcomes. Bioimpedance spectroscopy can aid health care 
professionals to identify CKD patients with fluid overload and provide 
individualized pharmacotherapy according to patient clinical needs. 
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CHAPTER 1 
GENERAL INTRODUCTION 
  
2 
 
1.1 Background 
Chronic kidney disease (CKD) is a general term used to describe heterogeneous 
disorders affecting structure and function of kidneys (Levey & Coresh, 2012). 
Currently CKD is affecting 10-16 % of adult population around the globe. 
Worldwide prevalence of disease is escalating with kidney diseases being 9
th
 leading 
cause of death in United States with total expenditure of more than 47.5 billion 
dollars in 2010 (Kearns et al., 2013; Coresh et al., 2007). Globally, more than 100 
countries (combined population >1 billion) have no facilities for RRT, attributing to 
more than 1 million annual deaths due to end stage renal disease (Ojo, 2014).  
According to 22
nd
 report of Malaysian dialysis and transplant registry (MDTR), the 
number of patients initiating dialysis as a mode of RRT has sharply increased from 
6702 in 2000 to 31,637 in 2013 resulting in a serious economic burden on health 
resources. The incidence of ESRD is escalating in Malaysia yet there is no record 
about prevalence as well as incidence of pre-dialysis stages of CKD. Based on one 
population based study in West Malaysia, the prevalence of CKD is estimated to be 
11.09 % which means that approximately 3.3 million of Malaysian population is at 
risk of developing ESRD (Hooi et al., 2013).  Although the results of this study 
needs confirmation by epidemiological data, still due to absence of latter, this 
population based study gives rough estimation. The alarming high incidence of 
ESRD is attributed to high incidence of diabetic kidney disease that accounts for 
58% of new ESRD patients, the highest incidence of diabetics undergoing ESRD 
(Huri et al., 2015).  
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Nearly fifteen years ago, kidney failure was considered as a public health concern 
due to its increasing incidence, poor outcomes and high cost. The rationale for global 
initiative to address increasing issues of kidney failure becomes evident with a 
substantially higher number of kidney disease patients with cardiovascular disease 
and premature death before reaching kidney failure (Levey et al., 2005). Due to lack 
of consensus of definition to categorize such patients in terms of disease severity and 
paucity of clinical trials in field of nephrology, many initiatives were taken to 
improve the outcomes and care of CKD patients before reaching kidney failure 
(Eckardt & Kasiske, 2009). The first and foremost step was to define disease severity 
and classify CKD patients in different levels of risk to ensure appropriate treatment 
and prevention of disease progression towards kidney failure. 
1.2 Definition 
In 2002, National kidney foundation (NKF) has proposed an evidence based 
definition of CKD in their Kidney Disease Outcome Quality Initiative (K/DOQI) 
clinical practice guidelines (Levey et al., 2003). According to these guidelines, the 
definition of CKD is based on three parameters; kidney damage, kidney function and 
time frame. In this definition, glomerular filtration rate (GFR) is used as a measure of 
kidney function. The normal value of GFR is approximately 120-130 ml/min/1.73m
2
 
in healthy adult. The definition of CKD has used a cut-off value of 
GFR<60ml/min/1.73m
2
 to define loss of kidney function as this value represents loss 
of approximately more than half of normal adult kidney function (Assiago et al., 
2009).  
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CKD is defined as kidney damage for 3 months as manifested by structural or 
functional abnormalities of the kidney with or without decreased GFR or 
GFR<60ml/min/1.73m
2
 for ≥ 3 months, with or without kidney damage (Levey et 
al., 2005). The definition of CKD according to KDOQI guidelines is summarized in 
Table 1.1. 
Table 1.1: Definition of Chronic kidney disease according to KDOQI guidelines 
Structural or functional abnormalities of the kidney for > 3 months 
1. Kidney damage (with or without decreased eGFR) manifested by 
 Pathological abnormalities (glomerular disease, vascular disease)  
 Markers of kidney damage 
o Abnormalities detected by urine (proteinuria, hematuria) 
o Abnormalities detected by blood (electrolyte imbalance, 
renal tubular syndrome) 
o Abnormalities detected by imaging i.e. ultrasound, CT 
scan, MRI (size, shape, obstruction) 
 Kidney transplantation 
2. Decreased GFR (<60ml/min/1.73m2) with or without kidney damage 
1.2.1 Classification/ Staging 
There are five stages of CKD as proposed by NKF-KDOQI. Stage 1 is the least 
complicated stage while stage 5 represents end stage renal disease (ESRD) with 
marked loss of kidney function. The KDOQI staging of CKD is shown in Table 1.2.  
Since the introduction of this staging system in 2002, many proposals have been 
suggested for its modification. In 2009, an International controversy conference was 
held that proposed three main modifications: (Levey et al., 2011) 
1. Addition of cause of disease (if known) to CKD staging as underlying cause  
is of prime importance in predicting outcome and selection of appropriate 
treatment 
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2. Division of CKD stage 3 (GFR 30-59 ml/min/1.73m2) into 3a (eGFR 45-59 
ml/min/1.73m
2
) and 3b (30-44 ml/min/1.73m
2
)  
3. Addition of albuminuria to CKD staging to assess disease severity 
Table 1.2: Classification of Chronic Kidney Disease 
CKD staging GFR (ml/min/1.73m
2
) Markers of Kidney 
damage 
1 ≥90 Required 
2 60-89 Required 
3 30-59 Not required 
4 15-29 Not required 
5 <15 Not required 
On the basis of these recommendations, Kidney disease improving global outcomes 
(KDIGO) proposed a CGA (cause, GFR, albuminuria) classification of CKD that is 
summarized in Table 1.3 (Levin & Stevens, 2014). 
Table 1.3: KDIGO classification of chronic kidney disease 
GFR category GFR 
(ml/min/1.73m
2
) 
Level of kidney function 
G1 ≥90 Normal or high 
G2 60-89 Mild decreased 
G3a 45-59 Mild to moderate decreased 
G3b 30-44 Moderate to severe decreased 
G4 15-29 Severe decreased 
G5 ≤15 Kidney failure 
Albuminuria 
category 
AER (mg/24 hour) Level 
A1 <30 Normal to mild increased 
A2 30-300 Moderate increased 
A3 >300 Severe increased 
Abbreviations: GFR: glomerular filtration rate; AER: albumin excretion rate 
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1.3 Assessment of kidney function 
Kidneys perform essential functions of eliminating metabolic waste products (urea, 
creatinine), reabsorption of nutrients (glucose, amino acids, water), maintaining body 
pH (by reabsorbing biocarbonates and excreting hydrogen ion), osmolality regulation 
(balance between water and electrolytes by maintaining urine concentration and 
water reabsorption), maintenance of blood pressure (renin-angiotensin aldosterone 
system)  and secretion of hormones (erythropoietin, calcitriol, renin) to regulate 
systemic and renal hemodynamics (Hall, 2015). Assessment of kidney function is 
done to identify severity of disease. Based on definition and staging of CKD, the key 
measure to assess kidney function is glomerular filtration rate (GFR) (Stevens et al., 
2006).  
1.3.1 Glomerular filtration rate 
The GFR is the sum of filtration rate of all the functioning nephrons in glomeruli. 
GFR is almost equal to the total number of nephrons and size of glomeruli; therefore, 
in clinical practice GFR is normalized to body surface area (BSA) to take account of 
different body sizes. The normal value of GFR is 120 -130 ml/min/1.73m
2 
in young 
adults (aged 25 years) after adjustment for BSA (Soveri et al., 2014). There is no 
standardized method available for measurement of GFR. It can be measured 
indirectly by measurement of urinary clearance of inulin, a gold standard for 
measurement of GFR. Inulin is not routinely used in clinical practice as it needs 
continuous bolus administrations along with timed urine collection i.e. a method that 
is used to collect all urine samples for a specified time interval (Berg et al., 2011).  
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1.3.2 Serum creatinine as marker of kidney function 
Serum creatinine is the most widely used endogenous marker of kidney function in 
routine clinical practice (Rule et al., 2004; Myers et al., 2006). It is produced by non-
enzymatic degradation of creatine in skeletal muscles and dietary intake of proteins. 
Although creatinine fulfills the criteria of an ideal marker by being freely filtered 
through glomerulus, neither reabsorbed nor metabolized by kidney but still there are 
some inherent limitations of using creatinine as marker of kidney function. Some of 
these limitations are listed below: (Coresh et al., 2003; Stevens et al., 2006) 
 Dietary variation in creatinine production 
 Creatinine production depends on muscle mass suggesting lower values in 
women, elderly and cachexia patients 
 Approximately 40% of urinary creatinine is produced by proximal tubules so 
it overestimates GFR 
 Decreased creatinine secretion by certain drugs such as cimetidine, 
trimethoprim, ranitidine 
 Extra renal elimination of creatinine (degradation by intestinal flora) 
particularly in patients with impaired kidney function  
1.3.3 Renal function predictive equation 
Renal function predictive equations estimate GFR by relying upon serum creatinine, 
demographic variables that effect GFR and various correction factors (Florkowski & 
Chew-Harris, 2011). The main purpose of development of such equations is to 
measure extent of kidney function clinically without undergoing expensive and time 
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consuming procedures. Three widely accepted and clinically used renal function 
predictive equations are given in Table 1.4 (Earley et al., 2012). 
Table 1.4: Commonly used renal function predictive equations 
Equation 
(year) 
Outcome Formula 
CG equation 
(1976) 
(CrCl) (140 – age) × (wt in kg) × (0.85 if fe) / (72 × Scr 
mg/dl) 
MDRD 
formula 
(1999) 
eGFR 175 × (0.011312 × sCr)
-1.154
 × age
-0.203
 × 0.742 (if fe) 
× 1.212 (if black) 
CKD-EPI 
equation 
(2009) 
eGFR 141 × min (Scr/k ‗ 1)α × max (Scr/k ‗ 1) -1.209 × 0.993 
age
 × 1.018 (fe) × 1.159 (black) 
For female: k= 0.7, α= -0.329 
For male: k=0.9, α=  -0.411 
CG:Cockroft and Gault, CKD-EPI:chronic kidney diseas-epidemiology, CrCl: 
creatinine clearance, eGFR:estimated glomerular filtration rate, fe:female, 
MDRD:modification of diet in renal disease, min:minute, Scr:serum creatinine, 
wt:weight, k and α represent constants 
1.3.3(a) Limitations of predictive equations 
The inherent limitation associated with renal function predictive equations is the use 
of serum creatinine that is not a sensitive renal biomarker. It is affected by several 
renal and non-renal factors that are independent of both kidney function and kidney 
injury. Moreover, these equations tend to show variations in result among different 
populations. Such populations include obese, multi ethnicities, any condition leading 
to unusual muscle mass, pregnancy and patients with high GFR (Lin et al., 2003; 
Froissart et al., 2005). Conclusively, all estimating equations are mathematical 
derivations and no equation is ideal for entire population (Botev et al., 2011). On the 
basis of data, CKD-EPI equation shows improved performance for eGFR near or 
above 60 ml/min/1.73m
2
 and has almost similar performance to MDRD equation for 
low eGFR (<60 ml/min/1.73m
2
) (Levey et al., 2009). 
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1.3.4 Measurement of proteinuria 
Proteinuria or albuminuria is used to assess kidney damage (Table 1.5). A spot urine 
or dipstick proteinuria is only sensitive to assess albuminuria (excretion of low 
molecular weight protein) and insensitive to assess proteinuria. Ideally a 24 hour 
urine collection is done to assess proteinuria. Due to cumbersome nature of timed 
urine collection, a spot urine specimen is widely used to assess albumin to creatinine 
ratio as indicator of proteinuria (Eknoyan et al., 2003). 
Table 1.5: Measures of urinary albumin and protein 
Characteristics Albumin 
excretion rate 
(mg/day) 
Protein excretion 
rate (mg/day) 
Albumin: Creatinine 
ratio (mg/g) 
Normal <30 mg/day <150 mg/day 
30 mg albumin /g 
creatinine 
Microalbuminuria 30-300 mg/day ---- 
30-300 mg albumin/ g 
creatinine 
Proteinuria >300 mg/day 500-3500 mg/day 
>300 mg albumin/g 
creatinine 
Nephrotic range ----- >3500 mg/day ---- 
1.4 Prevalence of CKD in Asia 
It is difficult to estimate accurate prevalence or incidence of CKD because of 
asymptomatic nature of disease and lack of National renal registry (NRR) for non-
dialysis dependent CKD patients (stage 1-stage 4). Renal registries of most countries 
focus on ESRD patients receiving renal replacement therapy (RRT) i.e. dialysis or 
transplantation. Moreover, lack of generalizability of biomarkers and methods to 
estimate GFR leads to biased prevalence (Levey & Coresh, 2012).   
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 Based on population based surveys and health screening programs, the prevalence of 
CKD can be estimated. The prevalence of CKD in Asia varies from 10-18 percent 
that is not much different from other parts of the world. However, due to paucity of 
data in Asian countries, the exact burden and cost associated with disease is still not 
clear (Hamer & Nahas, 2006). A summary of prevalence of CKD in different Asian 
countries is shown in Table 1.6. 
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Table 1.6: Prevalence of Chronic Kidney Disease in Asia  
Author 
[Reference ] 
Country 
Study design, no. of 
participants 
Participants characteristics Overall Prevalence of CKD 
Ninomiya et al., 
2005 
Japan (East Asia) 
Prospective cohort study, 
n=2634 
42 % male, 58% female with 
age 40 years and above 
10.3 % with MDRD equation 
Chen et al., 2005 China (East Asia) 
Cross sectional survey with 
random sampling, n=15540 
48 % male, 52 % female with 
age range of 35-74 years 
2.5 % with MDRD equation 
Konta et al., 
2006 
Japan (East Asia) 
Cross sectional survey, 
n=2321 
44 % male, 56 % female with 
age above 40 years 
28.8 % with CG equation 
Li et al., 2006 China (East Asia) 
Community based cross 
sectional survey, n=2310 
49 % male, 51 % female with 
age 40 years and above 
4.9 % with MDRD equation 
Perkovic et al., 
2007 
Thailand (South East 
Asia) 
Cross sectional survey with 
stratified cluster sampling, 
n=5146 
49 % male, 51% female with 
age range of 35- over 65 
13.81% with MDRD, 21.04% 
with CG equation 
Ito et al., 2008 
Vietnam (South East 
Asia) 
Prospective community based 
survey with random 
sampling, n=8504 
35% male, 75 % female with 
age 40 years and above 
3.1% with CG, 3.6% with 
MDRD adjusted with Japanese 
co-efficient 
Zhang et al., 
2008 
China (East Asia) Cross sectional survey with 
systematic sampling, 
n=13,925 
Male to female ratio 1:18:1, with 
age range of 18 - less than 70 
years 
13 %  with MDRD equation 
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Table 1.6: Continue… 
Author 
[Reference ] 
Country Study design, no. of 
participants 
Participants characteristics Overall Prevalence of 
CKD 
Hosseinpanah et 
al., 2009 
Iran (West Asia) Cross sectional study with 
TLGS cohort, n= 10063 
42% male, 58 % female with 
age over 20 years 
18.9 % with MDRD 
equation 
Prodjosudjadi et 
al., 2009 
Indonesia (South East 
Asia) 
Community based prospective 
survey, n=9412 
36% male, 64% female 12.5% with CG, 8.6 % 
with MDRD 
Sahin et al., 
2009 
Turkey (West Asia) Cross sectional study, n=1079 49% male, 51% female with age 
range of 18 to 95 years 
5.75% with MDRD 
equation 
Sabanayagam et 
al., 2010 
Singapore (South East 
Asia) 
Cross sectional survey with 
SPSP, n=4499 
48% male, 52% female with age 
range of 24-95 years 
5.5 % with MDRD 
Equation 
Yi et al., 2010 
 
Mongolia 
(East Asia) 
Cross sectional survey, n=4522 50% male, 50 % female with 
mean age of 50.3+14.3 years 
12.95 % with MDRD 
equation 
Alsuwaida et 
al., 2010 
Saudia Arabia (West Asia) Pilot community based 
screening, n= 491 
50% male, 50% female with 
mean age of 37.4+ 1.3 
5.7% with MDRD 
5.3% with CG equation 
Varma et al., 
2010 
India (South Asia) Cross sectional survey , n= 
3398 
66 % male, 34 % female with 
age above 18 years 
3.02 % with MDRD 
formula 
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Table 1.6: Continue… 
Author 
[Reference ] 
Country Study design, no. of participants Participants 
characteristics 
Overall Prevalence of 
CKD 
Kang et al., 
2012 
Kore (East Asia) Prospective cohort survey 
(KNHANES) with sampling weight 
method, n= 33276 
43% men, 57% female with 
age above 20 years 
With MDRD equation, 
1998: 10.3%, 2001: 18.2%, 
2005: 17.4%, 2009: 10.8 % 
Huda & Alam. 
2012 
Bangladesh (South 
Asia) 
Cross sectional survey, n= 1000 334 male, 666 female with 
age range of 15-65 years 
13.1 % with MDRD, 16 % 
with CG formula 
Singh et al., 
2013 
India (South Asia) Prospective cohort study,, n= 5588 55% male, 45 % female 
with age range of 18-98 
years 
5.09 % with MDRD formula 
Tennille et al., 
2013 
Philippines (South 
East Asia) 
Cohort survey (NNHeS) with stratified 
multi-stage cluster sampling, n=7702 
With age range of 20 – 70 
years 
6.7 % with CKD-EPI 
formula 
Hooi et al., 2013 West Malaysia, 
(South East Asia) 
876 individuals from the National 
Health and Morbidity Survey  
Adult (18 years and above) 9.07 with CKD-EPI formula 
Sharma et al., 
2013 
Nepal (South Asia) Community based screening with 
proportionate stratification, n=1000 
48 % male, 52 % female 
with age range of 20-60 
years 
6.3 % with MDRD 
Jessani et al., 
2014 
Pakistan (South 
Asia) 
Cross sectional survey, n=2873 52.2% female, Age 40 years 
and above 
12.5% with CKD-EPI 
formula 
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Out of total 21 studies, the prevalence of CKD was assessed via modification of diet 
in renal disease (MDRD) equation in 12 studies while chronic kidney disease 
epidemiology (CKD-EPI) equation was used by three studies (Hooi. 2013; Tennille 
et al., 2013; Jessani. 2014).  Majority of the studies have used MDRD equation to 
estimate prevalence of CKD, as MDRD equation was developed in 1999 while CKD-
EPI equation was developed almost after a decade in 2009 and was adapted for use in 
clinical practice later (Delanaye et al., 2013). One study used only Cockroft and 
Gault (CG) equation (Konta et al., 2013). Five studies used both MDRD and CG 
equation (Perkovic et al., 2007; Ito et al., 2008; Prodjosudjadi et al., 2009; 
Alsuwaida et al., 2010; Huda & Alam, 2013). In studies using both MDRD and CG 
equation, the prevalence of CKD was notably higher with CG equation as compared 
to MDRD equation. Study conducted by Ninomiya et al., reported prevalence of 
CKD in Japan as 10.3 % with MDRD equation while one year later another study 
conducted in Japan reported prevalence of CKD as 28.8% with CG equation 
(Ninomiya et al., 2005; Konta et al., 2006). Both these studies were conducted with 
participants above 40 years and with almost similar sample size i.e. 2634 versus 
2321, respectively. The much higher reported difference in prevalence of CKD in 
similar population belonging to same geographical area leads to confusing results. 
Although we cannot compare both studies directly because both studies used 
different set of population as participants but still as the characteristics of population 
matches therefore such remarkable difference of 18.5 % seems unacceptable. 
Disparities in prevalence of CKD owing to different predictive equation further 
necessitates need of NRRs for early stages of CKD and a uniform criteria to estimate 
burden of disease. 
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1.5 Risk factors of CKD 
Due to asymptomatic nature of disease, CKD remains undiagnosed in 80-90% cases 
in its early stages (Chadban et al., 2003; John et al., 2004). According to World 
Health organization (WHO), ―a risk factor is any attribute or characteristics of an 
individual that increases the likelihood of developing a disease‖ Clinical risk 
stratification plays an important role in early detection of CKD and ensures 
interventions at the earliest possible stage (WHO, 2004). Risk factors for CKD can 
be broadly classified into 3 main types as described in Table 1.7 (Levey et al., 2005).  
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Table 1.7: Categorization of risk factors of CKD 
Factors Description Type  
Susceptibility 
factors 
Factors that increase 
susceptibility to kidney disease 
Old age, family history, 
obesity, ethnicity 
Initiation factors Factors that directly initiate 
kidney disease 
Hypertension, diabetes, 
autoimmune disorders, 
urinary obstruction/stones, 
Toxicity of drugs, 
metabolic disorder 
Progression 
factors 
Factors that cause progression 
of kidney disease 
High blood pressure, 
diabetes (uncontrolled), 
proteinuria, smoking, 
metabolic 
disorder/dyslipidaemia 
A brief over-view of pathophysiology of these risk factors is discussed below.  
1.5.1 Obesity as risk factor of CKD 
Weisinger et al., first reported the relationship between obesity and decline in kidney 
function as manifested by heavy proteinuria (Weisinger et al., 1974). Obesity as 
defined by BMI > 25 kg/m
2
 is associated with a three fold increase risk of CKD as 
compared to non-obese i.e. BMI< 25 25 kg/m
2
 (Ejerblad et al.,2006). Obesity 
increases the metabolic demands of kidney leading to higher glomerular pressure and 
glomerular hypertrophy. This causes excretion of urinary albumin i.e. 
microalbuminuria initially and then proteinuria that directly damages kidney and 
causes ESRD (Garland, 2014). Obesity is frequently associated with 
hyperinsulinemia that directly damages structure of kidney by increasing depositions 
on kidney. This structural damage along with histological changes in kidney leads to 
focal segment glomerulosclerosis. Moreover, obesity also increases the risk of 
hypertension and diabetes, both of which are potential risk factors of CKD (Kramer, 
2006). 
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1.5.2 Metabolic syndrome (MS) as risk factor of CKD 
A metabolic syndrome (MS) is defined as concomitant presence of metabolic 
disturbance in glucose/ insulin metabolism and atherosclerotic risk factors 
(hypertension, dyslipidemia) accompanied by central obesity (Tanaka et al., 2006). 
In normal healthy individuals, the cumulative risk of CKD development is higher in 
subjects with metabolic syndrome as compared to subjects without metabolic 
syndrome; (10.6% versus 4.8%, p-value: 0.01) (Ninomiya et al., 2006). There are 
several inter-related mechanisms that underlie the effect of metabolic syndrome on 
renal function. Hyperinsulinemia associated with both diabetes and obesity causes 
glomerulopathy (Kramer, 2006; Tanaka et al., 2006). Gloermular hypertrophy, 
intraglomerular hypertension and hyperaldosteronism due to high blood pressure 
along with co-existing lipid disorders are all implicated in metabolic syndrome 
driven CKD (Gabbay et al., 2015). 
1.5.3 Hypertension as risk factor of CKD 
 
Hypertension is not only a cause but also a complication of CKD. Like diabetes, 
hypertension is a well described and one of the most potential risk factor for CKD. 
Compared to patients with normal BP, the risk of CKD development increases with 
higher BP. The HR of CKD development is 8.8 for stage 4 hypertension while the 
HR decreases to 6.3 for patients with stage 1 hypertension (Haroun et al., 2003). 
High blood pressure (>140/90 mmHg) causes faster decline in kidney function, 
increases risk of renal failure and cardiovascular diseases. Hypertension causes 
vasoconstriction of glomerular afferent arterioles to maintain renal blood flow and 
glomerular pressure. This vasoconstriction causes further increase in pressure load to 
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renal vasculature resulting in mechanical stretch of glomerular capillaries thereby 
causing glomeulosclerosis and renal artery stenosis (Ravera et al., 2006). 
1.5.4 Diabetes as risk factor of CKD 
Globally, diabetic kidney disease (DKD) is the leading cause of development of 
CKD. Diabetes mellitus (DM) not only causes CKD but it also serves as a potential 
independent risk factor of CKD progression. High blood sugar associated with DM 
directly increases glomerular permeability that results in leakage of contents from 
glomerulus (albuminuria, hematuria). Further DKD results in activation of RAAS 
that causes increase level of angiotensin II (a potent vasoconstrictor) resulting in 
vasoconstriction of afferent arterioles that ultimately increase albuminuria and overt 
nephropathy (Toth-Manikowski & Atta, 2015). 
1.5.5 Smoking as risk factor of CKD 
A number of biological mechanisms by which smoking causes kidney disease have 
been identified. Conclusively, smoking causes acceleration of renal artherosclerosis, 
altenates renal and systemic hemodynamics (increases glomerular permeability, 
enhance albuminuria) and causes endothelial dysfunctions (Shankar et al., 2006; 
Ishizaka et al., 2008). 
1.5.6 Proteinuria as risk factor of CKD 
Proteinuria is a widely accepted marker of kidney damage that is associated with 
diagnosis, prognosis as well as treatment of kidney disease. It causes increase 
glomerular capillary artery pressure causing increase pore size of basement 
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membrane effecting proximal tubule protein reabsorption (Levey et al., 2009). 
Proteinuria is strongly associated with arterial stiffness that causes high blood 
pressure and endothelial dysfunction (Clausen et al., 2001; Agarwal & Light, 2009). 
1.5.7 Family history as risk factor of CKD 
Mutation in genes that cause structural abnormalities in kidney (podocin, non-muscle 
myosin heavy chain) causes chronic glomerulonephritis. Moreover, genes causing 
sympathetic activation of nervous system (chromogranin A) leads to hypertension 
associated ESRD (McClellan et al., 2009). 
1.5.8 Advance age as risk factor of CKD 
It is a well-documented fact that GFR decreases 0.75-1ml/min/1.73m
2
 in all healthy 
individuals after 30 years of age (Berg, 2006). Moreover, the risk of developing 
CKD increases with advance age because other risk factors (hypertension, diabetes) 
for kidney disease are more prevalent in elderly. Ageing is a non-regulatory risk 
factor for development of CKD that is positively associated with arterial 
atherosclerotic change (Chen et al., 2009). 
1.5.9 Autoimmune disorders as risk factor of CKD 
Autoimmune disorders such as systemic lupus erythematosus (SLE) and IgA 
nephropathy cause glomerular disease In such cases, autoantibodies are produced 
within body that are deposited on glomerular membrane causing inflammation 
(glomerulonephritis) and scarring (glomerulosclerosis) (Levey et al., 2005). 
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1.5.10  Infections as risk factor of CKD 
Certain infections are associated with development of early or rapid glomerular 
disease. Human immunodeficiency virus (HIV) causes HIV-associated nephropathy 
that rapidly causes kidney failure due to massive proteinuria (Wyatt et al., 2008). 
Infective endocarditis is also associated with development of glomerular disease by 
causing renal lesions. Acute post strepto-coccal glomerulonephritis (PSGN) is 
another example of kidney damage as a result of infection. Streptococcus bacteria 
does not directly damages kidney rather the infection causes over production of 
antibodies by immune system that are then deposited on the basement membrane of 
kidney leading to glomerular disease (Levey & Coresh, 2012). 
1.5.11 Urinary tract obstructions/ stones as risk factor of CKD 
Urinary tract obstructions or severe urinary tract infections frequently cause transient 
renal dysfunction. In few cases, it can cause chronic renal failure. The pathological 
mechanism involves renal atrophy along with interstitial fibrosis and inflammation 
(Hong et al., 2010). Moreover, hydronephrosis (swelling of kidney due to 
accumulation of urine) causes renal dysfunction (Levey & Coresh, 2012). 
1.5.12 Drug induced nephrotoxicity as risk factor of CKD 
Drug induced nephrotoxicity is common with certain drugs that are routinely used in 
clinical practice. As most of the drugs concentrate and reabsorb in proximal tubules 
cells of nephron, they cause cytotoxicity by damaging mitochondria of tubules and 
increase oxidative stress.This results in generation of free radicals causing acute 
tubulointerstitial nephritis (TIN). Such drugs include aminoglycosides, amphotericin 
